Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review

Pfizer and Valneva’s VALOR Phase III trial for PF-07307405 shows about 73% efficacy at preventing confirmed Lyme disease, but the primary endpoint's 95% confidence interval is wide (15.8%–93.5%), likely due to milder Lyme activity during the study; a separate analysis confirms the lower bound above 20%, supporting FDA-approval steps. The vaccine targets the OspA protein to block Borrelia burgdorferi in ticks, and if approved could significantly boost Lyme prevention for high-risk groups.